Cervical Cancer Partnering Reviewed by CurrentPartnering12 Mar 2012 • by Natalie Aster
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
Insightful recent research review “Cervical Cancer Partnering 2007-2012” by CurrentPartnering provides understanding and access to the cervical cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of cervical cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cervical cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Cervical Cancer Partnering 2007-2012
Published: February, 2012
Price: US$ 995,00
This data driven report contains over 50 links to online copies of actual cervical cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
More information can be found in the report “Cervical Cancer Partnering 2007-2012” by CurrentPartnering.
To order the report or ask for sample pages contact email@example.com